PureTech Health PLC (GB:PRTC)
LSE:PRTC
Want to see GB:PRTC full AI Analyst Report?
PRTC Stock Chart & Stats
134.80 p
0.20 p(0.14%)
At close: 4:00 PM EST
134.80 p
0.20 p(0.14%)
Day’s Range― - ―
52-Week Range104.71 p - 148.00 p
Previous CloseN/A
Volume88.39K
Average Volume (3M)444.90K
Market Cap
£301.35M
Enterprise Value205.09M
Total Cash (Recent Filing)£279.00M
Total Debt (Recent Filing)£19.76M
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding243,418,180
10 Day Avg. Volume437,187
30 Day Avg. Volume444,904
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.30
Price to Sales (P/S)85.14
P/FCF Ratio-4.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£240.00Price Target Upside78.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.58
Revenue Forecast (FY)£10.30M
Bulls Say, Bears Say
Bulls Say
Hub-and-spoke Monetization ModelPublic-listing progress at Seaport and an increased stake validate PureTech’s venture‑builder model and demonstrated ability to scale and monetize founded entities. This structural capability to create sellable or investable businesses underpins repeatable, non‑dilutive value creation over the medium term.
Clinical Program Advancement (Gallop LYT‑200)Robust Phase Ib safety and dose selection for LYT‑200 materially de‑risks a lead program and enables a clear regulatory path. A registration‑enabling trial would shift program funding models and long‑term value potential, reducing binary program risk if execution follows clinical signals.
Relatively Strong Balance SheetA sizable equity cushion and low absolute debt provide financial flexibility to support multi‑year development timelines. While the cushion has shrunk from prior years, current capital resources and low leverage reduce short‑term insolvency risk and enable participation in founded‑entity financings.
Bears Say
Persistent Negative Cash FlowSustained negative operating and free cash flow forces reliance on balance‑sheet resources or external financing for ongoing R&D and trial starts. Over multiple quarters this erodes equity headroom and increases execution risk for late‑stage programs if capital markets or monetization windows tighten.
Funding And Execution Risk For Late‑stage ProgramsMajor value inflection depends on third‑party financing execution for large Phase III/registration trials. Failure or delay in securing partner funding could force deeper internal funding, dilution, or program delays, making long‑term value generation contingent on successful capital markets or partner deals.
Very Low, Volatile Revenue And EarningsMinimal and milestone‑driven revenue means recurring cash inflows are unpredictable and insufficient to fund development. Structural reliance on irregular monetizations or milestones increases sensitivity to timing risks and reduces ability to self‑fund growth or absorb clinical setbacks over the medium term.
PureTech Health News
PRTC FAQ
What was PureTech Health PLC’s price range in the past 12 months?
PureTech Health PLC lowest share price was 104.71 p and its highest was 148.00 p in the past 12 months.
What is PureTech Health PLC’s market cap?
PureTech Health PLC’s market cap is £301.35M.
When is PureTech Health PLC’s upcoming earnings report date?
PureTech Health PLC’s upcoming earnings report date is Aug 27, 2026 which is in 77 days.
How were PureTech Health PLC’s earnings last quarter?
PureTech Health PLC released its earnings results on Apr 29, 2026. The company reported -0.202 p earnings per share for the quarter, missing the consensus estimate of -0.143 p by -0.059 p.
Is PureTech Health PLC overvalued?
According to Wall Street analysts PureTech Health PLC’s price is currently Undervalued.
Does PureTech Health PLC pay dividends?
PureTech Health PLC does not currently pay dividends.
What is PureTech Health PLC’s EPS estimate?
PureTech Health PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PureTech Health PLC have?
PureTech Health PLC has 243,418,180 shares outstanding.
What happened to PureTech Health PLC’s price movement after its last earnings report?
PureTech Health PLC reported an EPS of -0.202 p in its last earnings report, missing expectations of -0.143 p. Following the earnings report the stock price went down -4.154%.
Which hedge fund is a major shareholder of PureTech Health PLC?
Currently, no hedge funds are holding shares in GB:PRTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PureTech Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
£240.00 (78.04% Upside)
£240.00 (78.04% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.20%
12-Months-Change
Fundamentals
Return on Equity
-31.83%
Trailing 12-Months
Asset Growth
-17.38%
Trailing 12-Months
Company Description
PureTech Health PLC
PureTech Health plc, a biopharmaceutical company established in Boston, Massachusetts, in 2015, functions as a clinical-stage firm primarily within the United States. It is dedicated to discovering, developing, and bringing to market medical treatments for a wide range of severe conditions, including inflammatory, fibrotic, and immunological diseases, challenging cancers, lymphatic and gastrointestinal disorders, and various neurological and neuropsychological ailments. The company's portfolio features KarXT, a therapy targeting muscarinic acetylcholine receptors for schizophrenia and psychosis associated with Alzheimer's disease. PureTech also employs a regenerative biology platform to address issues like androgenetic alopecia and epithelial aging, alongside an immunomodulation platform for both acute and chronic inflammatory disorders. Additional offerings include oral therapies derived from specific bacterial consortia of the human microbiome, and interventions for cognitive dysfunction often accompanying depression, multiple sclerosis, post-COVID, ICU recovery, and cancer-related conditions. Its technological innovations further encompass hematopoietic stem cell-based therapies for blood cancers, a voice-analysis platform for identifying health shifts, and a specialized technology enabling the oral delivery of biologics, vaccines, and other complex drugs. Currently in development, PureTech is advancing LYT-100 for lymphedema and other lymphatic flow disorders, as well as LYT-200 (an IgG4 monoclonal antibody designed to target galectin-9) and LYT-210, both aimed at solid tumors. Its pipeline also leverages advanced platforms such as Glyph for synthetic lymphatic targeting chemistry, Orasome technology for the oral administration of macromolecule payloads, a meningeal lymphatics platform addressing Alzheimer's and Parkinson's diseases, and the Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc maintains significant collaboration and licensing agreements with notable pharmaceutical partners, including Boehringer Ingelheim International GMBH, Eli Lilly and Company, Imbrium Therapeutics L.P., and Shionogi & Co., Ltd.
PRTC Stock 12 Month Forecast
Average Price Target
240.00 p
▲(78.04% Upside)
Technical Analysis
Avacta Group plc
―
ImmuPharma
―
Scancell Holdings
―
4basebio UK Societas
―
Arecor Therapeutics PLC
―
Options Prices
Currently, No data available
---